• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cognition Therapeutics Inc.

    1/19/24 3:07:49 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGTX alert in real time by email
    SC 13G 1 cgtx_11824.htm PATHSTONE FAMILY OFFICE, LLC cgtx_11824.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    COGNITION THERAPEUTICS INC
    (Name of Issuer)
    Common stock
    (Title of Class of Securities)
    19243B102
    (CUSIP Number)
    October 13, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 19243B102
           
    1
    NAME OF REPORTING PERSON
    Pathstone Family Office, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    271957427
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    2,205,377
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    7.53%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 19243B102
    ITEM 1(a). NAME OF ISSUER:
    COGNITION THERAPEUTICS INC
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    2403 Sidney Street
    Pittsburgh, PA 15203
    ITEM 2(a). NAME OF PERSON FILING:
    This statement is being filed by Pathstone Family Office, LLC, (Pathstone or the Reporting Person). Pathstone is a registered investment adviser under Section 203 of the Investment Advisers Act of 1940. The shares to which this Schedule 13G relates are owned directly by the accounts managed by Pathstone.
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    10 Sterling Blvd
    Suite 402
    Englewood, NJ 07631
    ITEM 2(c). CITIZENSHIP:
    Delaware
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common stock
    ITEM 2(e). CUSIP NUMBER:
    19243B102
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    2,205,377
    (b) Percent of class:
    7.53%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    0
    (ii) shared power to vote or to direct the vote:
    0
    (iii) sole power to dispose or direct the disposition of:
    0
    (iv) shared power to dispose or to direct the disposition of:
    0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Not Applicable
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not Applicable
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not Applicable
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not Applicable
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 19243B102
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    January 18 2024
    Pathstone Family Office, LLC
    By:
    /s/ Rebecca A Judd
    Name:
    Rebecca A Judd
    Title:
    Associate Director
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $CGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGTX

    DatePrice TargetRatingAnalyst
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    11/3/2021$27.00Buy
    B. Riley Securities
    11/3/2021$22.00Outperform
    Oppenheimer
    More analyst ratings

    $CGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Doyle John Brendan covered exercise/tax liability with 9,692 shares, decreasing direct ownership by 2% to 404,710 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      5/2/25 5:53:52 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO & President Ricciardi Lisa covered exercise/tax liability with 6,619 shares, decreasing direct ownership by 0.74% to 887,066 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      2/18/25 4:29:37 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Caggiano Anthony covered exercise/tax liability with 5,296 shares, decreasing direct ownership by 1% to 418,554 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      2/18/25 4:28:44 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cognition Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously

      12/19/24 7:33:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Cognition Therapeutics from Overweight to Neutral

      7/30/24 6:19:11 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on Cognition Therapeutics with a new price target

      B. Riley Securities initiated coverage of Cognition Therapeutics with a rating of Buy and set a new price target of $27.00

      11/3/21 8:37:44 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

      PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements. "John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. We look forward to leveraging his skills, his relationships on Wall Street, and his strategic insights as we move forward together as a company," said Lisa Ricciard

      5/1/23 7:30:44 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

      PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®. "We are now enrolling participants in three clinical studies: two for mild-to-moderate Alzheimer's disease and one for dementia with Lewy bodies with plans to commence enrollment in studies for early Alzheimer's disease and dry age-related macular degeneration in the near-term,

      10/11/22 8:00:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

      PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the addition of Ellen B. Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition's board, having served as chief financial officer and treasurer for Fortune 500 companies, and as a board member for c

      11/3/21 8:00:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cognition Therapeutics Inc. (Amendment)

      SC 13G/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      2/7/24 7:01:44 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cognition Therapeutics Inc.

      SC 13G - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      1/19/24 3:07:49 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Cognition Therapeutics Inc. (Amendment)

      SC 13D/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)

      11/13/23 5:25:24 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    SEC Filings

    See more
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      6/3/25 7:39:52 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      6/2/25 6:01:27 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      5/8/25 7:35:46 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

      Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute   PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has received an anonymous philanthropic donation to substantially fund an expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The generous donation comes from the family of a DLB patient who was treated with zervimesine in the Phase 2 SHIMMER study. Through this open-label EAP, participants will be provide

      6/3/25 7:30:02 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

      PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD). "Dry AMD is driven by a number of factors that contribute to the death of retinal cells, leading to irreversible vision loss," stated Mary Hamby, PhD, vice president of research. "Preclinical research presented at ARVO supports our understanding of zervime

      5/9/25 7:30:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

      Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine's potential across degenerative disease indications PURCHASE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported topline results today from the Phase 2 COG2201 ‘MAGNIFY' trial of zervimesine (CT1812) in adults with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The results show zervimesine-treated participants had 28.6% slower GA

      5/8/25 7:30:31 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & President Ricciardi Lisa covered exercise/tax liability with 28,960 shares, was granted 631,300 shares and bought $30,001 worth of shares (38,851 units at $0.77), increasing direct ownership by 207% to 893,685 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      2/4/25 4:11:53 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ricciardi Lisa bought $9,975 worth of shares (5,700 units at $1.75), increasing direct ownership by 2% to 291,345 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      3/14/24 4:34:10 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    Financials

    Live finance-specific insights

    See more
    • Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

      - End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "During our first quarter of 2025 and in recent weeks, we continued to advance our Alzheimer's disease and dementia with Lewy bodies (DLB

      5/7/25 7:30:15 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

      Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup 2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call PURCHASE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year en

      3/20/25 7:00:26 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

      PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 20, 2025, before the market open. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference Call Information: Telephone Access:  US/Canada Toll-Free Dial-in Number: (877) 704-4453International Dial-In Number: (201) 389-0920Conference I

      3/13/25 4:05:30 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care